[Skip to Navigation]
October 1963

Studies on the Pharmacology of Chloroquine: Recommendations for the Treatment of Chloroquine Retinopathy

Author Affiliations

Washington, DC and Bethesda, Md
From the Departments of Biochemistry and Medicine, Georgetown University School of Medicine, and from the Ophthalmology Branch, National Institute of Neurological Diseases and Blindness, National Institutes of Health, US Public Health Service, Department of Health, Education and Welfare, Bethesda 14, Md.

Arch Ophthalmol. 1963;70(4):474-481. doi:10.1001/archopht.1963.00960050476009

Introduction  Chloroquine (7-chloro-4- (4-diethylamino1-methylbutylamino) quinoline (Fig 1) was originally developed as an antimalarial agent. In recent years it has been found to be beneficial in a variety of diseases, including rheumatoid arthritis, discoid and systemic lupus erythematosus. When used as a malarial suppressive, 500 mg of chloroquine salt are given once a week. In the treatment of diseases other than malaria, chloroquine is administered in a much larger dosage and more frequently, usually 250 to 750 mg daily.1The occurrence of a characteristic retinopathy following the long-term daily ad- ministration of chloroquine has now been well documented.2 The fact that the retinal lesion usually develops after one or more years of drug ingestion, plus the remarkably large accumulation of chloroquine in body tissues and organs,3-5 suggests that the retinopathy may be due to high chloroquine levels in the ocular tissues. The present report concerns the finding of

Add or change institution